Aquestive Therapeutics, Inc. (AQST) analyst actions
AQST analyst actions moved a median of -0.25% by the close. Rating and price-target actions on AQST in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the AQST overview →
10 measured AQST analyst action events.
| Middle 50% of AQST analyst action reactions | -1.28% to +0.92% |
|---|---|
| Median reaction (to close) | -0.25% |
| Measured reactions | 10 |
Half of the 10 AQST analyst action events with a measured close landed between -1.28% and +0.92%; 40% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Reach Out | Press release | -0.00% | -1.48% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Reach Out | Press release | -0.19% | -0.66% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Reach Out | Press release | -0.11% | +1.47% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Reach Out | Press release | +0.00% | +0.13% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Reach Out | Press release | -0.12% | -0.49% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Reach Out | Press release | +0.24% | +1.19% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Reach Out | Press release | -0.50% | +0.00% | |
| AQST Lawsuit Alleges Analyst Slashed Price Target - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Analyst Slashed Price Target: SueWallSt | Press release | +0.00% | -4.95% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Reach Out | Press release | -0.46% | +1.52% | |
| Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™ | Press release | -3.50% | -3.50% |
More AQST: earnings → · SEC filings → · AQST overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| INSYS THERAPEUTICS (INSY) | 731 | +0.00% | 50% |
| Myovant Sciences Ltd. Common Shares (MYOV) | 728 | 0.00% | 49% |
| RETROPHIN INC (RTRX) | 723 | +0.06% | 52% |
| IsoRay, Inc. (DE) (ISR) | 722 | -0.01% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.